Focused On-demand Library for Ecto-ADP-ribosyltransferase 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q93070

UPID:

NAR4_HUMAN

Alternative names:

ADP-ribosyltransferase C2 and C3 toxin-like 4; Dombrock blood group carrier molecule; Mono(ADP-ribosyl)transferase 4; NAD(P)(+)--arginine ADP-ribosyltransferase 4

Alternative UPACC:

Q93070; Q9BZ50; Q9BZ51; Q9HB06

Background:

Ecto-ADP-ribosyltransferase 4, known by alternative names such as ADP-ribosyltransferase C2 and C3 toxin-like 4, Dombrock blood group carrier molecule, Mono(ADP-ribosyl)transferase 4, and NAD(P)(+)--arginine ADP-ribosyltransferase 4, plays a crucial role in cellular processes through its enzymatic activity. This protein, identified by the UniProt accession number Q93070, is involved in the post-translational modification of proteins, a fundamental mechanism for regulating protein function and signaling pathways.

Therapeutic significance:

Understanding the role of Ecto-ADP-ribosyltransferase 4 could open doors to potential therapeutic strategies. Its involvement in key cellular processes highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.